Janus kinase inhibitors in severe alopecia areata: balancing patient expectations with clinician safety considerations
- 4 December 2025
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (3) , 514-515
Abstract
An ethical dilemma of a patient with severe alopecia areata insisting on treatment with a novel oral Janus kinase inhibitor, despite the dermatologist expressing reservations about the patient’s cardiovascular risk factors.Keywords
This publication has 3 references indexed in Scilit:
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysisFrontiers in Pharmacology, 2025
- European expert consensus statement on the systemic treatment of alopecia areataJournal of the European Academy of Dermatology and Venereology, 2024
- Methotrexate for alopecia areata: A systematic review and meta-analysisJournal of the American Academy of Dermatology, 2019